|
1) Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006; 24: 4764-74
|
|
|
|
2) Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007; 19: 1731-41
|
|
|
|
|
|
3) Demetri GD, Benjamin R, Blanke CD, et al. NCCN task force report: Optimal management of patients with gastrointestinal stromal tumor (GIST)-expansion and update of NCCN clinical practice guideline. J Natl Cancer Inst. 2004; 2 (supple. 1): S1-26
|
|
|
|
|
|
4) Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005; 16: 566-78
|
|
|
|
|
|
5) Kubota T. Gastrointestinal stromal tumor (GIST) and imatinib. Int J Clin Oncol. 2006; 11: 184-9
|
|
|
|
|
6) Mudan SS, Conlon KC, Woodruff JM, et al. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 2000; 88: 66-74
|
|
|
|
|
|
7) Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002; 33: 466-77
|
|
|
|
|
|
8) Pawlik TM, Vauthey JN, Abdalla EK, et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg. 2006; 141: 537-43
|
|
|
|
|
|
9) Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007; 25: 1107-13
|
|
|
|
|
|
10) Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006; 24: 4764-74
|
|
|
|
|
|
11) Debiec-Rychter M, Sciot R, Le Cesne A, et al. Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006; 42: 1093-103
|
|
|
|
|
|
12) Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. 2006; 93: 304-11
|
|
|
|
|
|
13) DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007; 245: 347-52
|
|
|
|
|
|
14) Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006; 24: 2325-31
|
|
|
|
|
|
15) Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007; 245: 341-6
|
|
|
|
|
|
16) Hasegawa J, Kanda T, Hirota S, et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors under imatinib therapy. Inter J Clin Cancer. 2007; 12: 212-7
|
|
|
|
|
|
17) Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumors crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer. 2005; 41: 1751-7
|
|
|
|
|
|
18) Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-38
|
|
|
|
|
|
19) Nunobe S, Sano T, Shimada K, et al. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol. 2005; 35: 338-41
|
|
|
|
|
|
20) Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006; 244: 176-84
|
|
|
|
|